Responses
Regular and young investigator award abstracts
Clinical trials in progress
426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
